Who are ASC42's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Oral chenodeoxycholic acid stimulation, Ursodeoxycholic acid, Cholic Acids, Placebo Combined With Ursodeoxycholic Acid, Doxycycline and tauroursodeoxycholic acid, Obeticholic Acid Tablets（OCA）.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/asc42.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ASC42 — Competitive Intelligence Brief

ASC42 (ASC42) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: FXR agonist. Area: Gastroenterology.

phase 1 FXR agonist FXR Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

ASC42 (ASC42) — Gannex Pharma Co., Ltd.. ASC42 is a potent and selective FXR agonist that modulates bile acid metabolism and inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ASC42 TARGET	ASC42	Gannex Pharma Co., Ltd.	phase 1	FXR agonist	FXR
Oral chenodeoxycholic acid stimulation	Oral chenodeoxycholic acid stimulation	Lars Kristian Munck	marketed	Bile acid receptor agonist	FXR (farnesoid X receptor), TGR5
Ursodeoxycholic acid	Ursodeoxycholic acid	University of Oxford	marketed	Bile acid	Farnesoid X receptor (FXR), TGR5 receptor
Cholic Acids	Cholic Acids	Mirum Pharmaceuticals, Inc.	phase 3	Bile acid replacement therapy	Farnesoid X receptor (FXR) and TGR5 signaling pathways
Placebo Combined With Ursodeoxycholic Acid	Placebo Combined With Ursodeoxycholic Acid	Xijing Hospital of Digestive Diseases	phase 3	Bile acid	Farnesoid X receptor (FXR), TGR5
Doxycycline and tauroursodeoxycholic acid	Doxycycline and tauroursodeoxycholic acid	Fondazione IRCCS Policlinico San Matteo di Pavia	phase 3	Combination therapy (antibiotic + bile acid derivative)	Matrix metalloproteinases, FXR (farnesoid X receptor), TGR5 (G-protein coupled bile acid receptor 1)
Obeticholic Acid Tablets（OCA）	Obeticholic Acid Tablets（OCA）	Nanjing Chia-tai Tianqing Pharmaceutical	phase 3	Farnesoid X receptor (FXR) agonist	FXR (Farnesoid X Receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (FXR agonist class)

Dr. Falk Pharma GmbH · 1 drug in this class
Gannex Pharma Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ASC42 — Competitive Intelligence Brief. https://druglandscape.com/ci/asc42. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab